PMS-SILDENAFIL TABLET

国家: 加拿大

语言: 英文

来源: Health Canada

有效成分:

SILDENAFIL (SILDENAFIL CITRATE)

可用日期:

PHARMASCIENCE INC

ATC代码:

G04BE03

INN（国际名称）:

SILDENAFIL

剂量:

25MG

药物剂型:

TABLET

组成:

SILDENAFIL (SILDENAFIL CITRATE) 25MG

给药途径:

ORAL

每包单位数:

4

处方类型:

Prescription

治疗领域:

PHOSPHODIESTERASE TYPE 5 INHIBITORS

產品總結:

Active ingredient group (AIG) number: 0136261001; AHFS:

授权状态:

APPROVED

授权日期:

2012-11-13

产品特点

PRODUCT MONOGRAPH
PR PMS-SILDENAFIL
Sildenafil tablets (as sildenafil citrate)
25 mg, 50 mg and 100 mg
cGMP-Specific Phosphodiesterase Type 5 Inhibitor
Treatment of Erectile Dysfunction
PHARMASCIENCE INC.
DATE OF REVISION:
6111 Royalmount Ave., Suite 100
August 9, 2016
Montreal, Quebec
H4P 2T4
www.pharmascience.com
SUBMISSION CONTROL NO: 196963
_ _
_ _
_pms-SILDENAFIL Product Monograph _
_Page 2 of 49_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
............................................................. 3
SUMMARY PRODUCT
INFORMATION.....................................................................................
3
INDICATIONS AND CLINICAL USE
..........................................................................................
3
CONTRAINDICATIONS
................................................................................................................
3
WARNINGS AND PRECAUTIONS
..............................................................................................
4
ADVERSE REACTIONS
................................................................................................................
7
DRUG INTERACTIONS
..............................................................................................................
13
DOSAGE AND ADMINISTRATION
..........................................................................................
16
OVERDOSAGE
.............................................................................................................................
17
ACTION AND CLINICAL PHARMACOLOGY
.........................................................................
18
STORAGE AND STABILITY
......................................................................................................
21
SPECIAL HANDLING INSTRUCTIONS
....................................................................................
21
DOSAGE FORMS, COMPOSITION AND
PACKAGING.......................................................... 21
PART II: SCIENTIFIC INFORMATION
..............